|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






IM/Ambulatory care 





Neurology 





Key Words: anticonvulsants pain
| The first 150 words of the full text of this article appear below. |
METHODS
Data sources:
Medline (up to April 2003); the Cochrane Central Register of Controlled Trials (up to April 2003); review article references; books on headache; contact with drug companies, authors, and experts; and hand searches of Headache and Cephalalgia.
Study selection and assessment:
randomised controlled trials (RCTs) that compared anticonvulsants given regularly during headache free intervals in adults >18 years of age with placebo, no intervention, other drug treatments, or behavioural or physical therapies. Methodological quality was assessed using the Jadad 5 point scale.
Outcomes:
headache frequency (number of migraine attacks measured at 28 d), headache index measures (frequency and intensity or duration), and adverse events.
MAIN RESULTS
15 RCTs met the selection criteria. Anticonvulsants investigated were divalproex sodium (5001500 mg daily [4 RCTs]), topiramate (50200 mg daily [3 RCTs]), sodium valproate (8001500 mg daily [2 RCTs]), gabapentin (12002400 mg daily [2 RCTs]), carbamazepine (dose not reported [1 RCT]), clonazepam (1 mg
Alexander W Chessman, MD
Medical University of South Carolina
Charleston, South Carolina, USA
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |